<DOC>
	<DOC>NCT01377792</DOC>
	<brief_summary>A phase IV clinical trial, multicentric (3 Hospitals in Madrid) controlled, prospective, open and randomized of long-term treatment with hypertonic saline in cystic fibrosis patients. The purpose of this study is to verify if the long term inhalation (48 weeks) of major volume (10 ml) increases the free time without pulmonary exacerbation, and if this increase is superior to the obtained with the inhalation of the standard volume (5 ml) that has been advocated.</brief_summary>
	<brief_title>Study of Long-term Treatment With Hypertonic Saline in Patients With Cystic Fibrosis</brief_title>
	<detailed_description />
	<mesh_term>Fibrosis</mesh_term>
	<mesh_term>Cystic Fibrosis</mesh_term>
	<criteria>Clinical diagnosis of Cystic fibrosis Over 6 years old FEV1 over than 30% Must be able to perform a spirometry Must be able to perform induced sputum Must tolerate the maximum dose of 10 ml hypertonic saline No oral neither intravenous treatment within the previous 2 weeks before the beginning of the study No treatment with hypertonic saline in the 2 weeks before No clinical diagnosis of Cystic Fibrosis No tolerance of 10 ml of hypertonic saline Positive pregnancy test No tolerance of Beta2agonist Treatment with corticosteroids FEV1 &lt; 30% Liver and/or lung transplantation Oxygen treatment Hospital admission within the 4 previous weeks Oral or intravenous antibiotic treatment within the 2 previous weeks Smokers Pulmonary colonisation with Burkholderia cepacia complex</criteria>
	<gender>All</gender>
	<minimum_age>6 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2013</verification_date>
	<keyword>hypertonic saline</keyword>
	<keyword>cystic fibrosis</keyword>
	<keyword>pulmonary inflammation</keyword>
	<keyword>pulmonary exacerbation</keyword>
</DOC>